Augmedix, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Debt (Details)

Debt (Details) - USD ($)		1 Months Ended				3 Months Ended
Debt (Details) - USD ($)	Apr. 11, 2020	Mar. 25, 2021	Oct. 31, 2018	May 31, 2017	Jun. 30, 2015	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Debt (Details) [Line Items]
Maintain minimum amount						$ 2,000,000
Outstanding balance of note payable								$ 2,893,667
Exercisable and expire			The warrants have an exercise price of $96.24 per share and $106.17 per share, are immediately exercisable and expire in June 2025 and July 2027, respectively.
Maturity date description				Pursuant to the Sub Agreement, a final payment of $650,000 was payable at the maturity date in April 2023.
Amortized discount						33,921	$ 35,902
Unamortized discount						1,740,044		194,816
Interest expense						246,231
Remaining unamortized debt discount						$ 160,895
Description of debt						the final payment of $1,125,000 as both a discount and an increase to the principal amount of the debt. The Company also capitalized certain lender and legal costs associated with the Loan Agreement totaling $232,199, which were recorded as a discount to the loan. The aggregate discount of $1,752,611 is being amortized to interest expense over the repayment term of the Loan and Security Agreement. The Company amortized $12,567 of the discount to interest expense during the three months ended March 31, 2021. At March 31, 2021, the remaining unamortized discount was $1,740,044.
Outstanding balance						$ 2,180,300		$ 2,180,300
Investment agreement, description						the Lender and its affiliates a right to purchase in the Company’s future private equity financings up to a total $3,000,000 (if the Company only draws the first tranche) or $3,400,000 (if the Company draws the second tranche) at the same per share purchase price and terms as other investors in such private equity financings.
Warrant [Member]
Debt (Details) [Line Items]
Purchase of shares (in Shares)			91
Warrant exercise price (in Dollars per share)			$ 106.17
Security agreement [Member]
Debt (Details) [Line Items]
Borrowings amount					$ 3,500,000
Interest rate								3.62%
Security agreement [Member] \| Prime rate [Member]
Debt (Details) [Line Items]
Interest rate					0.50%
Sub Agreement [Member]
Debt (Details) [Line Items]
Borrowings amount				$ 10,000,000
Interest rate								12.00%
Final payment				650,000
Legal cost				279,757
Amortized discount				$ 1,195,012
PPP Loan [Member]
Debt (Details) [Line Items]
Interest rate	1.00%
Principal amount	$ 2,180,300
Description of debt	The PPP Loan matures in two years and bears interest at a rate of 1% per year, with all payments deferred through the six-month anniversary of the date of the PPP Loan. Principal plus accrued unpaid interest is to be paid in one payment two years after the date of this note and may be prepaid by the Company at any time prior to maturity without penalty. The Company may apply for forgiveness of amounts due under the PPP Loan, with the amount of potential loan forgiveness to be calculated in accordance with the requirements of the CARES Act based on payroll costs, any mortgage interest payments, any covered rent payments and any covered utilities payments during the 8-24 week period after the origination date of the Loan.
Outstanding balance						$ 2,180,300
Commercial bank [Member]
Debt (Details) [Line Items]
Maintain minimum amount						$ 2,000,000
Purchase of shares (in Shares)			234
Warrant exercise price (in Dollars per share)			$ 96.24
Loan and Security Agreement [Member]
Debt (Details) [Line Items]
Description of debt		the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Eastward Fund Management, LLC, as the lender (“Lender”) to establish a loan facility which provides for borrowings in the aggregate principal amount of up to $17,000,000, which are available to be drawn in two tranches. The first tranche of $15,000,000 was funded on March 31, 2021. The second tranche of $2,000,000 is available, at the Company’s request, between October 30, 2021 and November 30, 2021, provided the Company achieves certain revenue and EBITDA thresholds. Outstanding borrowings under the Loan Agreement are secured by a first priority lien on substantially all of the personal property assets of the Company, including the Company’s intellectual property. The Company is required to pay only interest during the first 18 months after funding of the tranche and thereafter, the Company shall repay such loan amount in 30 consecutive equal monthly installments of principal plus accrued interest. The loan facility bears an annual interest rate of the prime rate as published in the Wall Street Journal, subject to a floor 3.25%, plus 8.75%. On the final repayment date, Company is also obligated to pay a final payment fee equal to seven and one-half percent (7.5%) of the amount of the applicable advance.				In connection with the Loan Agreement, the Company issued the Lender warrants with a fair value of $395,412, which was recorded as a discount to the loan, to purchase up to 346,500 shares (increasing to 392,700 shares upon funding of the second tranche) of common stock that were immediately vested upon funding with an exercise price of $3.00 per share and a term of the earlier of i) March 24, 2031 and ii) the third anniversary of the Company’s listing on Nasdaq.